Toinv I hold out some hope that having Sanjay Lakhotia, someone with an actual biotech track record, in a senior management position will lead to some value creation and recognition for shareholders. That being said I find it extremely frustrating that Don can only manage to do PP's valuing Zenith at about $300M despite the sale of Constellation setting a much higher price bar for a mid-stage epigenetic cancer therapeutic.